- summary:
- The markets hardly recover from Deepseek shock and have just faced commercial identification winds. However, these arrows are among the extremist values.
The homogeneous feelings ruled the stock markets for the best part of last week, as investors remain cautious about the potential impact of a vigorous trade war. However, some stocks have shown flexibility and seemed likely to remain in the upward trend in chaos. The shares of NVIDIA, Glaxosmithkline (GSK) and the Taiwan Taiwan manufacturer TSCM are among them.
Nafidia
The price of the NVIDIA shares appears to have survived the storm caused by Deepseek in the last week of January. As far as you have not yet received standard levels of $ 140, the FUD morale surrounding the arrow has been dissipated. Many analysts deal with that although Deepseek is effective, it is unlikely to eat in a large part of the NVIDIA market.
The leading technology companies may continue to focus on artificial intelligence as their growth limits in the foreseeable future. The strongest back winds of NVIDIA shares are likely to come in the coming weeks of profit reports. This will be the first time that the company will issue revenue numbers for Black Cells, and there is strong evidence that expects expected profits. The CEO of NVIDIA (NASDAQ: NVDA) has previously described the demand for chips as “crazy”.
NVIDIA share price prediction
Axis: NVIDIA share axis at 119.35. Working above this level will prefer buyers to be in control. Otherwise, the declining momentum will prevail.
Resistance: The first resistance at $ 122.10. The second in 123.90 dollars
Support: S1 at $ 117.60. Breaking this level will nullify the bullish direction. The second support is likely to be at $ 115.45.
Glaxosmhkline
The momentum is attributed to the price of Glaxosmithkline (LSE: GSK) to strong profits in the quarter ended in December 2024. On Tuesday, the company has informed sales of 8.12 billion pounds for medium expectations of 7.75 billion pounds. EPS stood at GBX 23.2, overcoming GBX 19 expectations.
Also, the company expects revenue growth between 3 % -5 % in 2025 and targets revenues of 51 billion pounds in 2031, driven by focusing on specialization medicine. More investment in specialized medicine is seen as a crucial growth path, as vaccines face difficult times amid a decrease in general support.
The Senate is likely to approve the candidate of US Health Minister Robert F. Kennedy Junior, skeptical known in vaccines, by the Senate. This can push the era of low absorption of vaccines, adding credibility to the need to diversify revenue sources. The momentum is likely to be on the price of GSK driven by feelings in the short term, but strong basics prefer growth as well.
GSK price prediction
Axis: Axis stock in GBX 1,459.
Resistance: First Resistance in GBX 1,474. The second in GBX 1,489.
The first support in GBX 1,449 is likely to come, below that the bullish narration will be invalid. The second support in GBX 1,436.
Taiwan semiconductor manufacturer (TSM)
Like NVIDIA, the price of TSM shares was under pressure in the last week of January due to Riot Deepsek. However, with the stability of dust, it appears that the world’s leading semiconductor chips seem unlikely to take care of the growth path. If anything, some analysts believe that Deepseek is a blessing for TSM.
According to the latest report issued by JP Morgan, if the large Deepseek R1 language model can be implemented on low power tools such as laptops and smartphones, this may lead to a significant increase in demand for artificial intelligence chips. This translates into more demand for TSM products (NYSE: TSM) and is ultimately preferred from the price of TSM. This news is likely to pay stocks in the coming days.
TSM price prediction
Pivot: Pivot Point at $ 203.08
Resistance: It is likely that the resistance is the first to be at $ 206.55, after which the next goal can come at $ 210.00
Support: Basic Support in $ 200.90. The collapse under that sign will nullify the bullish narration. The second support can come at $ 198.90.
